Objective: To find potential diagnostic
biomarkers for
ovarian cancer (OC), a prospective analysis of the expression of five
biomarkers in patients with intermediate-risk and their correlation with the occurrence of OC was conducted. Method: A prospective observational study was carried out, patients who underwent surgical treatment with benign or malignant ovarian
tumors in our hospital from January 2020 to February 2021 were included in this study, and a total of 263 patients were enrolled. Based on the postoperative pathological results, enrolled patients were divided into
ovarian cancer group and benign
tumor group (n = 135). The
ovarian cancer group was further divided into a mid-stage group (n = 46) and an advanced-stage group (n = 82). The basic information of the three groups of patients was collected, the preoperative imaging data of the patients were collected to assess the
lymph node metastasis, the preoperative blood samples were collected to examine
cancer antigen 125 (CA125),
carbohydrate antigen 19-9 (CA19-9), Neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), and the postoperative pathological data were sorted and summarized. Result: The average during of disease in the advanced
ovarian cancer group was 0.55 ± 0.18 years higher than the benign
tumor group (0.43 ± 0.14 years), p < 0.001. In the advanced
ovarian cancer group, the ratio of patients with the
tumor, node,
metastasis (TNM) stage IV (64.63%), with
tumor Grade stage II and III (93.90%), and without
lymph node metastasis (64.63%) was respectively more than that in the mid-stage group (accordingly 0.00, 36.96, 23.91%) (p < 0.001); The ratio of patients with TNM grade III in the mid-stage group (73.91%) was more than that in the advanced group (35.37%) (p < 0.001). The levels of the five
biomarkers: CA19-9, CA125, NLR, PLR, and
BDNF were different among the three groups (p < 0.001). Conclusion: CA19-9, CA125, NLR, PLR,
BDNF are five
biomarkers related to the occurrence of
ovarian cancer and are risk factors for it. These five
biomarkers and their Combined-Value may be suitable to apply in the diagnosis and the identification of
ovarian cancer in patients with intermediate-risk.